Peptide 101: Sermorelin Acetate

This issue leads with one peptide explained plainly, then the regulatory and research items worth your time. Sources are linked inline; every claim should be traceable.

Peptide 101: Sermorelin Acetate

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid growth hormone-releasing hormone (GHRH). It was FDA-approved in 1997 (as Geref) for the diagnosis and treatment of growth hormone deficiency in children, though the branded product was discontinued for commercial reasons (not safety concerns). It stimulates the pituitary gland to produce and release growth hormone in a physiological, pulsatile manner, and is now widely used off-label through compounding pharmacies for adult growth hormone optimization.

How it works

If growth hormone is like water from a faucet, direct GH injection is like pouring water from a bucket — you get a big splash all at once, and the body’s natural flow-control valve gets bypassed. Sermorelin instead taps the faucet handle, asking your body to turn the water on naturally, at its own pace, with the safety valve still working.

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary gland, stimulating the synthesis and secretion of endogenous growth hormone. Unlike exogenous GH injection, sermorelin preserves the hypothalamic-pituitary feedback loop, resulting in physiological pulsatile GH release with intact negative feedback via IGF-1 and somatostatin. This means the body can still regulate its own GH levels, reducing the risk of supraphysiological GH exposure.

What the evidence shows

Overall strength of the evidence, by our read: Strong Evidence. Some of what that rests on:

• Sermorelin for adult GH deficiency (1997) — Sermorelin increased GH and IGF-1 levels and improved body composition in GH-deficient adults
• Sermorelin effects on sleep and body composition (1997) — Sermorelin improved slow-wave sleep and body composition in healthy older adults
• Peptides in sports medicine (narrative review) (2026) — Human safety and efficacy data for sermorelin and similar peptides remain scarce; placebo effect noted as a mediator of perceived benefit.

Preliminary or early findings are not the same as proof. Any use beyond a peptide’s FDA-approved labeling (where one exists) is described here for educational purposes only and is not a recommendation.

Safety — what’s known, and what isn’t

Generally well-tolerated. Common side effects include injection site reactions (pain, redness, swelling), facial flushing, headache, and dizziness. Transient increases in cortisol and prolactin can occur. Because it works through the body’s natural feedback system, the risk of GH excess is lower than with direct GH injections. Rare side effects include hyperactivity and difficulty swallowing.

Recent research (2026): A critical review of peptide use in sport reported class-level risks, including cardiovascular strain, insulin resistance, and dyslipidemia, associated with supraphysiological or unregulated use of GHRH analogues such as sermorelin (Coutinho LFD, de Oliveira Neves LF, Camilo RP, DOI: 10.23736/S0022-4707.26.17773-1)

Reasons to avoid it, or to talk to a clinician first:

• Active malignancy or history of cancer
• Pituitary tumor or hypothalamic disorders
• Diabetic retinopathy
• Pregnancy or breastfeeding
• Children under 18 (unless for diagnosed GH deficiency under specialist care)

This is not a complete safety list. It is the set of things worth knowing before a conversation with a prescriber.

Questions worth bringing to a clinician

• What are my current IGF-1 levels and do I have a clinical indication for GH stimulation?
• How does sermorelin compare to direct GH therapy for my situation?
• What monitoring (IGF-1, blood glucose, etc.) is needed during treatment?

This week in peptides

Federal Acquisition Regulation: Revolutionary Federal Acquisition Regulation Overhaul Parts 1, 2, 4, 33, 39, 40, and 53

federal_register · 2026-06-23

OFPP, DoD, GSA, and NASA (collectively referred to as the Federal Acquisition Regulatory Council or FAR Council) are proposing to amend the Federal Acquisition Regulation (FAR) to implement Executive Order (E.O.) 14275, Restoring Common Sense to Federal Procurement. The E.O. directs the elimination of excessive acquisition regulations to stop the inefficient use of American taxpayer dollars. The FAR Council is issuing twelve proposed rules that collectively will streamline the FAR in its entiret

Source ↗

Advisory Committee; Science Board to the Food and Drug Administration; Renewal

federal_register · 2026-06-18

The Food and Drug Administration (FDA) is announcing the renewal of the Science Board to the Food and Drug Administration by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Science Board to the Food and Drug Administration for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 26, 2028, expiration date.

Source ↗

Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

federal_register · 2026-06-16

This proposed rule would codify the Medicare Drug Price Negotiation Program (“Negotiation Program”) and would establish certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. This proposed rule would also propose a modification to the fixed combination drug policy.

Source ↗

New research, translated

SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²

2027-01 · INTERVENTIONAL · semaglutide

SHAPE-ENDO is a single-center, open-label, pilot randomized clinical trial conducted at Hospital Universitari de Bellvitge in Barcelona, Spain.…

Source ↗

Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study

2026-09 · INTERVENTIONAL · semaglutide

Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine (‘ice’) to reduce their use. This study will treat people who use methamphetami…

Source ↗

A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or Obesity

2026-04-30 · INTERVENTIONAL · cagrilintide

The study is testing cagrilintide, a study medicine, to understand how it affects food intake and appetite in people with overweight or obesity. Participants will receive either cagrilintide or placebo, and which treatment participants get is decided by chance. Cagrilintide is the treatment being tested, while placebo looks like the study medicine but does not contain any active medicine. The stud…

Source ↗

What readers are asking

Topics we’ll be tracking:

• Effects of Weekly Semaglutide and Tirzepatide Therapy on APRI and FIB-4 Scores in Adults with Obesity: A Real-World 12-Month Study
• Efficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
• Sustained Low-Dose Semaglutide Is Linked to Broad-Spectrum Cardiometabolic Benefits, and Better Tolerability Profile over Low-Dose Tirzepatide, Motivating Semaglutide Microdosing Studies

---

About Sermorelin (this peptide)

Sermorelin (Geref) was an FDA-approved medication but the commercial product has been discontinued in the United States. It may still be available through compounding pharmacies under Section 503A of the FD&C Act. Compounded versions are not FDA-approved and may differ from the original product. Sermorelin is a prescription medication that requires a valid prescription from a licensed healthcare provider. Do not attempt to obtain or use this medication without proper medical supervision. Compounded versions of Sermorelin are NOT the same as FDA-approved products. Compounded drugs have not undergone FDA review for safety, efficacy, or manufacturing quality. The FDA has warned that compounded versions may contain different salt forms, concentrations, or impurities. Discuss the risks and regulatory status of compounded medications with your prescriber.

Medical disclaimer

This letter is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment, and no provider-patient relationship is created by reading it. Peptides and medications discussed may not be FDA-approved for the uses described. Always consult your healthcare provider before making any health decision. Read our full medical disclaimer.

---

This is a draft assembled automatically from our data pipelines and peptide profiles. The Peptide 101 section is fact-pulled from the profile and wants a short editorial polish before publishing. Not published until reviewed.